Eris Lifesciences Ltd · NSE:ERIS
Eris Lifesciences — Q4 FY20 Earnings Presentation
22 slides from Eris Lifesciences's earnings presentation, Jun 2, 2020
Slide 1: Investor presentation filing cover letter to stock exchanges
Date: June 02, 2020 To To BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza Dalal Street Bandra Kurla Complex Mumbai- 400001 Bandra (E) Mumbai-400051 Security Code: 540596 Symbol: ERIS SUBJECT: INVESTOR PRESENTATION Dear Sir/Madam, Pursuant to the requirem
Slide 2: Eris Lifesciences Ltd Q4 FY20 and FY20 Investor Presentation
ERIS LIFESCIENCES LTD Q4 FY 20 and FY 20 INVESTOR PRESENTATION 1
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and the underlying assumptions
Slide 4: Q4 FY20 – Covid-19 Pandemic
Q4 FY 20 – Covid 19 Pandemic In wake of the global pandemic, Eris was faced with 2 primary challenges: ensuring the safety of its employees, customers and vendors as well as ensuring continuity of business to serve doctors and patients Ensuring safety of • Roll out of health insurance policy for emp
Slide 5: Q4 Business Highlights
Q4 FY 20 – BUSINESS HIGHLIGHTS Market beating double digit growth: Eris outgrows market by 48% Eris sales grow 14.3% yoy vs IPM growth of 9.7% Chronic therapies continue to outperform market and sub chronic therapies regain momentum: Eris chronic therapies grow 19.6% yoy vs IPM growth of 12.1% Eris
Slide 6: Q4 Secondary Growth
Q4 FY 20 – SECONDARY GROWTH IPM ERIS 14.3% 9.7% IPM grew by Eris’s total sales TOTAL 9.7% grew by 14.3% IPM Eris 19.6% 12.1% 65% of Eris’ IPM’s Chronic therapies grew Chronic therapies grow 1.6x CHRONIC Revenue at 12.1% faster than market at 19.6%. IPM Eris 13.4% 22% of Eris’ IPM’s sub chronic thera
Slide 7: Q4 Income Statement
Q4 FY 20 – INCOME STATEMENT Consolidated Q4 FY 20 INR Millions Q4 FY20 Q4 FY19 yoy GR Q4 FY 20 Financial Performance Sale of Products 2,441 2,111 15.6% Other Operating Income 45 37 19.9% Revenue from Operations 2,486 2,148 15.7% 15.6 % 24.1 % 4.1 % Gross Profit 2,115 1,799 17.5% Gross Profit Margin
Slide 8: FY 20
FY 20 7
Slide 9: Moment of Pride
MOMENT OF PRIDE ERIS’ INDIA HEART STUDY IN INTERNATIONAL JOURNAL Our persistent efforts to promote science recognised by global institutions of hypertension European Society of Hypertension and International Society of Hypertension have jointly accepted our India Heart Study paper to publish in the
Slide 10: Patient Care Initiatives – Scientific Engagement with Doctors
PATIENT CARE INITIATIVES – SCIENTIFIC ENGAGEMENT WITH DOCTORS Scientific engagement with Doctors – our marketing divisions maintain their tenacious focus on Patient Care Initiatives while engaging with health care providers. This investment in promotion of science provides Eris an unhindered mindspa
Slide 11: FY20 – Business Highlights
FY 20 – BUSINESS HIGHLIGHTS Market beating double digit growth: Eris Healthcare enters into Disease Prevention with a meaningful product portfolio Eris sales grow 11.0% yoy vs IPM growth of 9.8% Clusters Chronic therapies continue to outperform market and sub chronic therapies regain momentum: Busin
Slide 12: Successfully Capitalising Off Patent Opportunities
FY 20 – BUSINESS HIGHLIGHTS Successfully Capitalising Off patent opportunities In December 2019, Vildagliptin, a prime molecule in Diabetes Care, went off patent. Vildagliptin is a 30,000 inr mn DPP 4 inhibitor – a class of oral diabetes drug that has evolved as the first line of defence in Diabetes
Slide 13: Successful Launch of In-licensing Product
FY 20 – BUSINESS HIGHLIGHTS Successful launch of In-licensing Product In Q3 FY 20 we launched Rariset, under our in-licensing agreement with Pharmanutra S.P.A for their patent protected Sucrosomial Iron Successful launch of Iron has a crucial role in Ante Natal Care as well as management of chronic
Slide 14: Business Redefined into Clusters
FY 20 – BUSINESS HIGHLIGHTS Business Redefined into 4 Clusters CARDIO CARDIO METABOLIC METABOLIC CNS ACUTE BUSINESSES -1 BUSINESSES -2 13
Slide 15: FY20 – Secondary Growth
FY 20 – SECONDARY GROWTH IPM ERIS 11.0% 9.8% IPM grew by Eris’s total sales TOTAL 9.8% grew by 11.0% IPM Eris 14.8% 10.8% 63% of Eris’ IPM’s chronic therapies Eris outgrew market, especially CHRONIC Revenue grew by 10.8% in Diabetes and Cardiac Care IPM Eris 9.9% 8.2% Sub chronic therapies 23% of Er
Slide 16: FY20 – Therapy Area Wise CAGR Over FY18 to FY20
FY 20 – THERAPY AREA WISE CAGR OVER FY 18 to FY 20 Chronic Therapies Sub Chronic Therapies Acute Therapies Diabetes Care = 29% of Revenue 23% of Revenue 14% of Revenue 5.2% Market Share * Glimisave Tendia Market grows Cyblex by 9.1% CAGR Renerve Eris degrows Top 3 Mother Brands Ginkocer by 4.7% outp
Slide 17: FY20 – Top 10 Mother Brands
FY 20 – TOP 10 MOTHER BRANDS Sales FY 20 Brand Market Market Share – FY 20 Rank (INR Mn) Growth Growth GLIMISAVE 2,462 Top 10 mother brands = 66% of sales ERITEL 1,373 RENERVE 1,079 TENDIA 750 OLMIN 670 Top 10 mother brands grew 15.2% yoy vs 11.3% yoy growth of their respective CYBLEX 634 markets LN
Slide 18: FY20 – Prescription Ranking
FY 20 - PRESCRIPTION RANKING Prescription Ranking* 4 3 3 CARDIOLOGY DIABETOLOGY GASTRO 3 9 CONSULTING NEUROLOGY PHYSICIAN Source: SMSRC * Rx Rank in Represented Market (MAT Feb’20) 17
Slide 19: FY20 – Financial Highlights
FY 20 – FINANCIAL HIGHLIGHTS Financial Highlight – FY 20 Financial Highlights – FY 18 to FY 20 9.4 % 6.8 % 1.8 % 13.1 % 6.9 % 0.4 % yoy growth yoy growth yoy growth CAGR in Sales CAGR in EBITDA CAGR in PAT in Sales in EBITDA in Net Profit FY 18 to FY 20 FY 18 to FY 20 FY 18 to FY 20 12,000 10,741 10
Slide 20: FY20 – Income Statement
FY 20 – INCOME STATEMENT Consolidated FY20 INR Millions FY20 FY19 yoy GR Sale of Products 10,582 9,672 9.4% Other Operating Income 159 150 6.1% Revenue from Operations 10,741 9,822 9.4% Gross Profit 9,025 8,285 8.9% Gross Profit Margin 84.0% 84.4% Employee Cost 2,053 1,907 7.7% as % of Revenue 19.1%
Slide 21: Shareholder Profile
SHAREHOLDER PROFILE Shareholding of Promoters and Top 15 Institutional Investors Others, FPI, 10.19% 0.66% As on As on As on Sr no Name of Shareholder 31-Mar-20 31-Dec-19 30-Sep-2019 369* 474* 451* Promoters, DIIS, 55.55% Promoters 55.55% 56.23% 56.23% 11.18% 1 ChrysCapital (Emerald Investment Limit
Slide 22: Thank You
THANK YOU ERIS LIFESCIENCES LTD KRUTI RAVAL INVESTOR RELATIONS kruti@erislifesciences.com 21